Letter to the Editor: Tumor Lysis Syndrome During Selpercatinib Treatment in a Patient with Medullary Thyroid Cancer

Thyroid. 2023 Sep;33(9):1130-1132. doi: 10.1089/thy.2023.0214. Epub 2023 Aug 10.

Authors

Simone De Leo¹, Matteo Trevisan², Giulia Vanessa Re Sartò³, Claudia Moneta², Marta Pirovano³, Carla Colombo^{1

4}, Laura Cosmai³, Laura Fugazzola^{1

4}

Affiliations

¹ Department of Endocrine and Metabolic Diseases, Endocrine Oncology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.
² Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
³ Division of Nephrology and Dialysis, ASST Fatebenefratelli-Sacco, Fatebenefratelli Hospital, Milan, Italy.
⁴ Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

PMID: 37463111
DOI: 10.1089/thy.2023.0214

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Neuroendocrine* / drug therapy
Humans
Thyroid Neoplasms* / drug therapy
Thyroid Neoplasms* / pathology
Tumor Lysis Syndrome* / etiology

Substances

selpercatinib

Supplementary concepts

Thyroid cancer, medullary